文献速递其他结缔组织病自身炎症与 IgG4 相关病

自身免疫与炎症性疾病基因工程治疗的新时代

A new era of genetic engineering for autoimmune and inflammatory diseases.
PubMed 文献 · Semin Arthritis Rheum · 2019-05-16

本文综述基因工程工具在自身免疫与炎症性疾病治疗中的快速进展,比较锌指核酸酶、转录激活样效应核酸酶与CRISPR/Cas9等基因编辑技术,总结病毒载体与非病毒递送方法,并介绍嵌合自身抗原受体T细胞、调节性T细胞、基因修饰造血干祖细胞移植及诱导多能干细胞在动物模型与人类自身免疫病中的临床前及初步人体经验。

要点

  • 基因编辑可在炎症病理的多个阶段进行干预,基因修饰细胞疗法较传统细胞治疗具有潜在优势。
  • CRISPR/Cas9等新工具较锌指核酸酶和转录激活样效应核酸酶是更近期发展的基因编辑手段。
  • 潜在适应方向包括单基因自身炎症病、自身耐受丧失、体液免疫介导的自身免疫病及炎症损伤组织的再生医学。

核心结论

  • 基因编辑技术快速发展并已应用于人类疾病治疗,为自身免疫与炎症性疾病提供多种潜在治疗路径。

研究设计与样本

  • 综述,围绕基因编辑工具的演变及其在自身免疫与炎症性疾病中的应用展开,涵盖递送方法、动物模型临床前实验与人类自身免疫病中基因编辑细胞的初步经验。

主要发现

  • 基因编辑工具可用于在炎症病理的多个阶段进行干预,基因修饰细胞疗法相较传统细胞疗法具多项潜在优势。
  • 综述比较了锌指核酸酶、转录激活样效应核酸酶与CRISPR/Cas9等基因编辑工具,并总结了病毒载体与非病毒递送技术。
  • 文中描述了嵌合自身抗原受体T细胞与调节性T细胞用于多基因病、基因修饰造血干祖细胞移植用于单基因病、修饰诱导多能干细胞用于再生医学的潜在用途。

临床怎么用

  • 对多基因自身免疫病可关注嵌合自身抗原受体T细胞与调节性T细胞的治疗探索。
  • 对单基因自身炎症病可关注基因修饰造血干祖细胞移植策略。
  • 对炎症损伤或破坏的组织可关注修饰诱导多能干细胞用于再生医学的方向。

局限性

  • 本文为综述,未报告具体研究样本量、效应数值或统计学结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic autoimmune and inflammatory diseases exhibit variable genetic factors. The tools for specific and efficient genetic engineering are developing at a dramatic pace and are now being applied to therapy of human diseases. Gene editing tools can be used to interdict the pathology of inflammation at multiple stages. Therapies utilizing genetically modified cells offer many potential advantages over traditional cellular therapy approaches. Monogenic autoinflammatory disease, loss of self-tolerance, autoimmune disease based in humoral immunity, and regenerative medicine for tissues deranged or destroyed by inflammation are potential pathologies that could be treated with therapies based in genetic editing technologies. In this review, we discuss the rapid evolution of technologies for genome editing and their applications for autoimmune and inflammatory diseases. We compare older-generation methods, including zinc-finger nucleases and transcription activator-like effector nucleases, with more-recently developed tools, mainly CRISPR/Cas9. Gene-editing tool delivery methods including viral vectors and non-viral technologies are summarized. Finally, pre-clinical experiments with gene editing for therapy of animal models of autoimmune and inflammatory disease, and initial experience with gene-edited cells in human autoimmunity are described. In this review, we discuss potential therapeutic uses of chimeric autoantigen receptor T cells and regulatory T cells for polygenic disease, genetically-modified hematopoietic stem and progenitor cell transplantation for monogenic disease, and modified induced pluripotent stem cells for regenerative medicine.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Ewart D, Peterson EJ, Steer CJ, et al. A new era of genetic engineering for autoimmune and inflammatory diseases. Semin Arthritis Rheum. 2019. PMID: 31146955. doi:10.1016/j.semarthrit.2019.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。